MiMedx Group, Inc (NASDAQ:MDXG) Stock Has Consensus Price Target of $8.57 According to Analysts

Posted by George Bondi on Oct 9th, 2026

MiMedx Group, Inc (NASDAQ:MDXG – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the seven ratings firms that are presently covering the company, MarketBeat reports. One analyst has rated the stock with a sell rating and six have issued a buy rating on the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $8.57.

MDXG has been the topic of several analyst reports. Raymond James Financial set a $8.00 price target on shares of MiMedx Group in a report on Monday, August 17th. Wall Street Zen raised shares of MiMedx Group from a “sell” rating to a “hold” rating in a research note on Saturday, August 29th. Seaport Research Partners downgraded shares of MiMedx Group to a “neutral” rating in a research report on Monday, August 17th. Weiss Ratings upgraded shares of MiMedx Group from a “sell (d)” rating to a “sell (d+)” rating in a research note on Thursday, August 27th. Finally, Craig Hallum upped their target price on shares of MiMedx Group from $6.00 to $8.00 and gave the stock a “buy” rating in a report on Thursday, August 27th.

View Our Latest Stock Report on MiMedx Group

Hedge Funds Weigh In On MiMedx Group

Several large investors have recently made changes to their positions in MDXG. BlackRock Inc. purchased a new stake in shares of MiMedx Group during the second quarter worth about $46,795,000. Nantahala Capital Management LLC bought a new position in MiMedx Group in the 2nd quarter worth approximately $18,355,075. Paradigm Capital Management Inc. NY bought a new position in MiMedx Group in the 2nd quarter worth approximately $15,681,000. Renaissance Technologies LLC grew its holdings in MiMedx Group by 22.4% during the 1st quarter. Renaissance Technologies LLC now owns 3,019,871 shares of the company’s stock valued at $11,928,000 after buying an additional 552,806 shares in the last quarter. Finally, Dimensional Fund Advisors LP raised its position in shares of MiMedx Group by 8.7% during the first quarter. Dimensional Fund Advisors LP now owns 2,694,002 shares of the company’s stock valued at $10,640,000 after buying an additional 214,633 shares during the last quarter. 79.15% of the stock is currently owned by hedge funds and other institutional investors.

MiMedx Group Stock Performance

Shares of MDXG opened at $4.62 on Tuesday. The business has a 50-day simple moving average of $4.50 and a two-hundred day simple moving average of $4.05. The company has a quick ratio of 4.79, a current ratio of 5.33 and a debt-to-equity ratio of 0.07. MiMedx Group has a 52 week low of $3.03 and a 52 week high of $7.97. The stock has a market cap of $673.41 million, a price-to-earnings ratio of 115.53 and a beta of 1.18.

MiMedx Group (NASDAQ:MDXG – Get Free Report) last posted its quarterly earnings data on Wednesday, July 29th. The company reported ($0.05) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.05). The firm had revenue of $64.36 million for the quarter, compared to analysts’ expectations of $63.46 million. MiMedx Group had a return on equity of 12.09% and a net margin of 1.76%. On average, analysts expect that MiMedx Group will post -0.1 EPS for the current year.

MiMedx Group Company Profile

(Get Free Report)

MiMedx Group, Inc is a regenerative healthcare company that develops, manufactures and markets human placental tissue allografts and related biomaterial products. Its products are derived from donated human placental tissue and are processed for use in healthcare settings, including wound care, surgery and orthopedic applications.

The company’s portfolio includes tissue allografts such as EPIFIX, EPIEFFECT, GRAFIX and AMNIOFIX. These products are designed to support the management of chronic and acute wounds, surgical reconstruction and other clinical procedures.